Skip to main content

Table 3 Pathological and immunohistochemical characteristics in patients with G-NENs (n = 135)

From: Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience

Variables

NET G1 (n = 39, %)

NET G2 (n = 7, %)

NEC G3 (n = 69, %)

MANEC (n = 20, %)

P value

Depth of invasion

    

<0.001

 T1

29 (74.4)

3 (42.9)

4 (5.8)

1 (5.0)

 

 T2

7 (17.9)

0 (0.0)

6 (8.7)

3 (15.0)

 

 T3

2 (5.1)

0 (0.0)

23 (33.3)

9 (45.0)

 

 T4

1 (2.6)

4 (57.1)

36 (52.2)

7 (35.0)

 

Lymph node metastasis

    

<0.001

 N0

36 (92.3)

3 (42.9)

4 (5.8)

3 (15.0)

 

 N1

3 (7.7)

4 (57.1)

65 (94.2)

17 (85.0)

 

Distant metastasis

    

0.001

 M0

39 (100.0)

5 (71.4)

60 (87.0)

14 (70.0)

 

 M1

0 (0.0)

2 (28.6)

9 (13.0)

6 (30.0)

 

TNM stage

    

<0.001

 I/II

36 (92.3)

3 (42.9)

4 (5.8)

2 (10.0)

 

 III/IV

3 (7.7)

4 (57.1)

65 (94.2)

18 (90.0)

 

Vascular invasion

0 (0.0)

2 (28.6)

33 (47.8)

8 (40.0)

<0.001

Immunohistochemical features

 CgA (+)

32 (82.1)

4 (57.1)

57 (82.6)

15 (75.0)

0.367

 Syn (+)

29 (74.4)

5 (71.4)

53 (76.8)

13 (65.0)

0.728

 NSE (+)

9 (23.1)

2 (28.6)

16 (23.2)

2 (10.0)

0.594

 CD56 (+)

16 (41.0)

4 (57.1)

38 (55.1)

5 (25.0)

0.086

  1. G-NENs gastric neuroendocrine neoplasms, NET G1 neuroendocrine tumor G1, NET G2 neuroendocrine tumor G2, NEC G3 neuroendocrine carcinoma G3, MANEC mixed adenoneuroendocrine carcinoma, TNM tumor-node-metastasis, CgA Chromogranin A, Syn synaptophysin, NSE neuron specific enolase